Seaweed – The Superfood Tackling Health Emissions And Food Security
As the world battles rising chronic disease and climate instability, seaweed is emerging as a rare solution to both. Once relegated to coastal cuisines, this fast-growing marine macroalgae is now surfacing in dietary supplements, snacks, bioplastics and even methane-reducing livestock feed.
Seaweed has emerged as a promising solution to help meet global food and material demands without expanding agricultural land. Researchers from institutions including the University of Queensland, International Institute for Applied Systems Analysis, and Commonwealth Scientific and Industrial Research Organization found that scaling up the cultivation of commercially valuable seaweed species could significantly ease pressure on terrestrial farming. These findings underscore seaweed's potential to support both food security and climate goals, provided land and ocean resources are managed in an integrated, sustainable way.
According to a Science Direct article, Western diets are deficient in fiber and essential micronutrients, contributing to gut imbalances, chronic inflammation, and metabolic dysfunction. Seaweed, particularly sugar kelp, naturally fills these gaps with a potent mix of insoluble fibers such as fucoidan, beta-glucan, alginate, and cellulose. When fermented by gut bacteria, these fibers produce short-chain fatty acids, compounds linked to improved insulin sensitivity, satiety, and immune health.
TOPSHOT - Captain John Lovett, 52, uses a knife to harvest kelp and throws keepers into a large bin ... More on the boat in Duxbury, Massachusetts on May 9, 2023. (Photo by Joseph Prezioso / AFP) (Photo by JOSEPH PREZIOSO/AFP via Getty Images)
Seaweed Health Support From The Ocean
OCEANIUM, a UK-based biotech founded by Karen Scofield Seal and Dr. Charlie Bavington, is using seaweed to support both people and planet. Their flagship product, OCEAN ACTIVES® H+, delivers a clinically proven 250 mg dose that improves the ratio of beneficial to harmful gut bacteria, specifically increasing Bifidobacterium while decreasing Enterobacteriaceae.
The company's proprietary green biorefinery process ensures their ingredients are bioavailable, food-safe, and traceable from sea to shelf. OCEANIUM is also collaborating with Wageningen University on dementia-prevention research through the gut-brain axis and working with Reading University to explore human and pet nutrition.
From a sustainability standpoint, seaweed requires no land, freshwater, or fertilizer, making it one of the most sustainable crops on Earth. According to the company, it supports six UN Sustainable Development Goals, absorbs CO₂ and nitrogen, and increases marine biodiversity.
OCEANIUM is not alone in the innovation game. PhycoHealth in Australia produces seaweed-based capsules targeting gut and skin health. FutureFeed, another Australian agritech company, has developed a seaweed-based cattle feed supplement that cuts methane emissions by over 80%, according to CSIRO.
Challenges Facing Seaweed And The Way Forward
Despite its potential, seaweed still faces hurdles to mainstream adoption. Limited processing infrastructure poses a bottleneck to scaling, and its taste and texture can be off-putting to some consumers. According to the OCEANIUM team, overcoming these challenges requires offering products in familiar, easy-to-use formats with a neutral flavor profile. Their approach focuses on refining seaweed into versatile ingredients that seamlessly integrate into everyday foods like snacks, soups, and protein bars. Just as crucial is consumer education, emphasizing seaweed's health benefits and sustainability value to build trust and encourage widespread use.
Pills of seaweed spirulina, chlorella on a wooden spoon close up. Vegetarian Super food with plant ... More protein
Seaweed is no longer a fringe ingredient, it is a frontier crop with the potential to nourish people and regenerate the planet. Backed by science, powered by innovation, and aligned with global sustainability goals, seaweed offers a rare convergence of health, climate, and economic opportunity. Seaweed brands are proving that with smart processing, strategic partnerships, and consumer education, seaweed can transcend its niche and become a mainstream force in food systems, bioeconomy, and environmental resilience. The path forward isn't without obstacles, but if cultivated with care, this marine resource could help reshape the future of both nutrition and planetary stewardship.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Ovarian Cancer Risk Rises Soon After IBS Diagnosis
TOPLINE: Women with a new diagnosis of irritable bowel syndrome (IBS) have a significantly higher risk for ovarian cancer at 3 months and 6 months post-diagnosis, but this risk is no longer elevated beyond 8 months. METHODOLOGY: Ovarian cancer often presents with nonspecific symptoms overlapping those of IBS. The frequency of misdiagnosis remains unknown, and not all IBS guidelines recommend screening for ovarian cancer. Researchers conducted a retrospective cohort study using US administrative claims data to compare ovarian cancer incidence in adult women with and without a new IBS diagnosis. Diagnostic codes were used to identify cases of IBS and ovarian cancer. TAKEAWAY: The cohort comprised 9804 women with IBS and 79,804 women without IBS, identified between January 2017 and December 2020. Women with IBS had a significantly higher risk for ovarian cancer at 3 months (hazard ratio [HR], 1.71; P = .02) and 6 months (HR, 1.43; P = .02), but not beyond 8 months post-diagnosis. Women with both IBS and endometriosis had an even greater risk for ovarian cancer at 3 months (HR, 4.20; P = .01), 6 months (HR, 3.52; P = .01), and after 1 year (HR, 2.67; P = .04). Increasing age was significantly associated with higher ovarian cancer incidence only in women younger than 50 years (HR, 1.07; P < .01), regardless of IBS status. IN PRACTICE: 'Identifying patient-specific risk factors, such as chronic pelvic pain or endometriosis, could help develop tailored risk profiles and improve the approach to personalized care in women with IBS-type symptoms,' the authors wrote. SOURCE: This study was led by Andrea Shin, Vatche and Tamar Manoukian Division of Digestive Diseases, University of California, Los Angeles. It was published online in Alimentary Pharmacology & Therapeutics. LIMITATIONS: The use of diagnostic codes for identifying IBS may have led to misclassification or reflected symptoms rather than confirmed and validated diagnosis. DISCLOSURES: This study received support from the National Institutes of Health. Some authors reported serving as consultants, advisors, and/or receiving research support from pharmaceutical and healthcare companies; one author reported having stock options. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
2 hours ago
- Medscape
Patients With Acromegaly Face Higher Cancer Risk
TOPLINE: Patients with acromegaly had significantly higher odds of developing leukemia/lymphoma or ovarian, breast, lung, or other cancers, many of which occurred at younger ages than typically seen in the general population. These data underscored the urgent need to integrate cancer screening protocols into routine care for patients with acromegaly to facilitate earlier detection and intervention. METHODOLOGY: Excess growth hormone secretion in patients with acromegaly increases the levels of insulin-like growth factor, a known cancer risk factor; however, the true prevalence of cancer in these patients is not well known. Researchers conducted a retrospective cohort analysis using data from a multinational research network platform to compare cancer prevalence in individuals with acromegaly and those without the condition. Patients with acromegaly (n = 10,207; mean age at disease onset, 43.2 years; 52.9% women) were matched with 102,070 individuals from the general population without the condition. TAKEAWAY: Patients with acromegaly had a 3.3-fold increased odds of developing leukemia/lymphoma (95% CI, 2.3-4.67), a 1.9-fold increased odds of developing ovarian cancer (95% CI, 1.3-2.8), a 1.8-fold increased odds of developing breast cancer (95% CI, 1.5-2.0), 1.9-fold increased odds of developing lung cancer (95% CI, 1.5-2.3), and a 1.5-fold increased odds of developing prostate cancer (95% CI, 1.3-1.8). The onset of certain cancers, specifically ovarian, lung, liver, and neuroendocrine, occurred much earlier (3.2-7.2 years) in patients with acromegaly than in control individuals from the general population. IN PRACTICE: 'Our findings suggest that acromegaly may play a bigger role in cancer risk than previously thought, highlighting the need for increased awareness and early cancer screening in this population,' said the lead researcher in a press release. SOURCE: This study was led by Hitam Hagog Natour, MD, Thomas Jefferson University Hospital in Philadelphia. It was presented on July 14, 2025, at the ENDO 2025: The Endocrine Society Annual Meeting in San Francisco. LIMITATIONS: This study did not report any specific limitations. DISCLOSURES: This study did not report any specific funding or conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
2 hours ago
- Medscape
Cancer Care Costs High Among Privately Insured Patients
TOPLINE: A recent analysis found that privately insured US patients with newly diagnosed cancer, especially those with more advanced disease, had 'substantial out-of-pocket costs.' Monthly out-of-pocket costs among these patients increased by a mean of almost $600, on average, but increased to nearly $720 per month for those with stage IV disease. METHODOLOGY: Out-of-pocket costs for cancer care in the US are rising, but most research has focused on Medicare beneficiaries. It's important to understand privately insured patients' financial burdens, especially with cancer rates growing among younger Americans. Researchers conducted a retrospective study of 19,656 patients with cancer, using a dataset that links claims from a large private insurer to the Surveillance, Epidemiology, and End Results cancer registry. Overall, 74.1% had breast cancer, 14.5% had colorectal cancer, and 11.4% had lung cancer. Analyses also included 26,502 individuals without cancer who were assigned pseudo – diagnosis date. Monthly out-of-pocket costs (copays, co-insurance, and deductibles) were calculated from claims and inflation-adjusted to 2024 US dollars. TAKEAWAY: After a cancer diagnosis, monthly out-of-pocket costs rose by $592, on average. Those added costs increased with disease stage, from $462 per month for stage 0 cancer to $720 per month for stage IV cancer. Out-of-pocket costs spiked in the month of diagnosis and remained elevated for 6 months compared with those in individuals without cancer — totaling an average of $4145 in cumulative additional costs (over 7 months). IN PRACTICE: 'In this cohort study, patients with private insurance were found to have high OOPCs [out-of-pocket costs] after an incident diagnosis of cancer, and those with the most advanced cancer had the highest OOPCs,' the authors wrote. 'The variability in OOPCs based on cancer stage underscores the need for policies such as paid sick leave, that address both insurance continuity and financial assistance, especially for patients with more advanced cancer.' SOURCE: This study, led by Liam Rose, PhD, Stanford University School of Medicine, Palo Alto, California, was published online in JAMA Network Open. LIMITATIONS: Differential insurance attrition could have affected the results: Patients with stage IV cancer were most likely to drop their coverage. The study could only capture direct medical costs, which misses other potential financial burdens, such as lost income and travel expenses. DISCLOSURES: This study received funding support through a grant from the American Cancer Society. One author reported receiving grants from the Department of Veterans Affairs and National Institutes of Health during the conduct of the study. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
